The short version of metabolic research fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-03-18. Anything still debated is marked as such rather than presented as settled.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; visual inspection |
| Solubility | Soluble in water and aqueous buffers | Depends on pH, purity, and counterion |
| Typical storage | -20 °C or below, desiccated | Protect from light; avoid repeated freeze-thaw after reconstitution |
| Common analytical method | Reversed-phase HPLC and mass spectrometry | Purity by HPLC; identity and mass by LC-MS or MALDI-TOF |
| Common synonyms | hGH fragment 176–191; AOD-9604 | Names vary in research and product labeling |
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
Kinases act upon many other molecules besides proteins, lipids, and carbohydrates. There are many that act on nucleotides (DNA and RNA) including those involved in nucleotide interconverstion, such as nucleoside-phosphate kinases and nucleoside-diphosphate kinases. Other small molecules that are substrates of kinases include creatine, phosphoglycerate, riboflavin, dihydroxyacetone, shikimate, and many others.
Individual harm, damage to public trust, and threats to national security are three categories of harm that may come as a result of whistleblowing. Revealing a whistleblower's identity can automatically put their life in danger. Some media outlets associate words like "traitor" and "treason" with whistleblowers, and in many countries around the world, the punishment for treason is the death penalty, even if whoever allegedly committed treason may not have caused anyone physical harm. In some instances, whistleblowers must flee their country to avoid public scrutiny, threats of death or physical harm, and in some cases criminal charges. Whistleblowers are often protected under law from employer retaliation, but in many cases, punishment such as termination, suspension, demotion, wage garnishment, and/or harsh mistreatment by other employees occurs. A 2009 study found that up to 38% of whistleblowers experienced professional retaliation in some form, including wrongful termination. Following dismissal, whistleblowers may struggle to find employment due to damaged reputations, poor references, and blacklisting. The socioeconomic impact of whistleblowing through loss of livelihood and family strain may also impact whistleblowers' psychological well-being. Whistleblowers often experience immense stress as a result of litigation regarding harms such as unfair dismissal, which they often face with little or no support from unions. Whistleblowers who continue to pursue their concerns may also face long battles with official bodies such as regulators and government departments.
=== Blood pool labeling === When 99mTc is combined with a tin compound, it binds to red blood cells and can therefore be used to map circulatory system disorders. It is commonly used to detect gastrointestinal bleeding sites as well as ejection fraction, heart wall motion abnormalities, abnormal shunting, and to perform ventriculography.
== Interactions == When combined with antidepressants of the MAOI or SSRI class, very high parenteral doses of 5-HTP can cause acute serotonin syndrome in rats. It is unclear if such findings have clinical relevance, as most drugs will cause serious adverse events or death in rodents at very high doses. In humans, 5-HTP has never been clinically associated with serotonin syndrome – although a case report suggests 5-HTP can precipitate mania when added to an MAOI. When combined with carbidopa (as a treatment for symptoms of Parkinson's disease), 5-HTP causes nausea and vomiting; however, this can be alleviated via administration of granisetron. Cases of scleroderma-like illness have been reported in patients using carbidopa and 5-HTP. Oral 5-HTP results in an increase in urinary 5-HIAA, a serotonin metabolite, indicating that 5-HTP is peripherally metabolized to serotonin, which is then metabolized. This might cause false positive results in tests looking for carcinoid syndrome. Due to the conversion of 5-HTP into serotonin by the liver, there could be a risk of heart valve disease from serotonin's effect on the heart, as based on preclinical findings. However, 5-HTP has not been associated with cardiac toxicity in humans. It has been suggested that 5-HTP may cause eosinophilia-myalgia syndrome (EMS), a serious condition which results in extreme muscle tenderness, myalgia, and blood abnormalities. However, there is evidence to show that EMS was likely caused by a contaminant in certain 5-HTP supplements.
Kipa-Williams explained that Marilyn "stumbles" across the family living out of their car on her way to work, and invites them to stay with her, but they initially turn her offer down. Gemma's pride stops her from accepting Marilyn's offer, until she realises that the family needs to come first. When John returns home, he is surprised to find the family in his house. Kipa-Williams believed John was jealous of Ari's connection with Marilyn, saying "John doesn't like the fact that Marilyn has this bond with Ari. He wishes she shared that connection with him, and John starts to grow jealous – it gets heated a few times." Symons explained that for Marilyn, letting the family stay with her is her way of paying back Ari for comforting her during the siege. She sees that the family is struggling and wants to help them settle in the Bay. John's opposition causes problems in his marriage, as he does not understand why Marilyn would invite the family to stay. Symons was excited about the Parata's introduction, as it gave everyone "a new energy to play off." The fractious nature of Ari and Tane's relationship comes to a head when they fight over their nephew. After Nikau gets fed up living with Ari and Gemma, he seeks out his uncle and stays the night at his place. When Tane drops him off in the morning, Ari accuses Tane of being "a bad influence" and the pair have a physical altercation by the road. Following a break-in at the Pier Diner, Constable Colby Thorne (Tim Franklin) is convinced the Paratas had something to do with it and he becomes "desperate" to pin the crime on them.
Sources: en.wikipedia.org
In August 2016, Taco Bell brought back its Pink Strawberry Starburst Freeze. In October 2015, Taco Bell launched a certified vegetarian menu. In August 2016, Taco Bell announced it would begin testing a mashup known as Cheetos Burritos at select Taco Bell restaurants On September 19, 2016, Taco Bell launched Airheads Freeze, a drink inspired by the candy Airheads White Mystery, and allow people to guess its flavor on social media. On September 15, 2016, Taco Bell introduced the Cheddar Habanero Quesarito, a quesadilla shelled burrito. In April 2017, Taco Bell announced that it would begin testing the Naked Breakfast Taco in Flint, Michigan in mid-April. The breakfast taco, which uses a fried egg as the shell for potato bites, nacho cheese, shredded cheddar, and bacon or sausage crumble. In 2017, the company released the Naked Chicken Chalupa that uses a chalupa shell made from chicken, using a similar idea to the Double Down and later that year the Naked Chicken Chips, which are chicken nuggets shaped like chips with nacho cheese. In July 2017, Taco Bell announced a partnership with Lyft in which Lyft passengers in Orange County, California, can request "Taco Mode" on their way to their destination from 9 PM to 2 AM, having a stop at Taco Bell. The program was cancelled after much negative feedback from drivers. On September 21, 2018, Taco Bell announced National Taco Day celebrating its global reach outside of the United States, to be celebrated in 20 countries. In January 2019, Taco Bell nearly doubled its television advertising spending to US$64 million.
== Feeding == The primary diet of the Wagler's pit viper consists of rodents, birds, and lizards. The pits, one on each side of the head between the eye and the nostril, are capable of detecting temperature difference of as little as 0.003 of a degree Celsius (0.0054 of a degree Fahrenheit).
== Ligands == The AMYRs are bound by amylin with high affinity, and by calcitonin with relatively lower affinity. In humans, calcitonin gene-related peptide (CGRP) is a selective agonist with a greater affinity towards AMY1 than AMY3, while its affinity for AMY2 isn’t well understood. Drugs that mimic Amylin to activate amylin receptors (called Amylin receptor agonists) are being developed as therapies for diabetes and obesity, and one, pramlintide, has been FDA approved as a treatment for diabetes. CGRP receptor antagonists which are being developed for migraine, may also act as antagonists for AMY1, which could be playing a role in their effects. Dual agonists of the amylin and calcitonin receptors (DACRAs) are under development for obesity. Amylin and its receptors are believed to play a role in Alzheimer's disease.
Other causes include the Kearns–Sayre syndrome (which seems to involve problems besides mitochondrial energy generation), serine deficiency, DHPR deficiency, and (in some older patients) pyridoxine dependent epilepsy. There are also cases of CFD not explained by genetic tests. Those are possibly secondary to using medications that consume methyl bases during metabolis or to oxidative stress or other forms of toxic insult.
Sources: en.wikipedia.org
=== Pharmacodynamics === As a glucocorticoid, dexamethasone is an agonist of the glucocorticoid receptor (GR). It is highly selective for the GR over the mineralocorticoid receptor (MR), and in relation to this, has minimal mineralocorticoid activity. This is in contrast to endogenous corticosteroids like cortisol, which bind to and activate both the GR and the MR. Dexamethasone is 25 times more potent than hydrocortisone (cortisol) as a glucocorticoid. Its affinity (Ki) for the GR was about 1.2 nM in one study. The activation of the GR by dexamethasone results in dose-dependent suppression of the hypothalamic–pituitary–adrenal axis (HPA axis) and of production of endogenous corticosteroids by the adrenal glands, thereby reducing circulating endogenous concentrations of corticosteroids like cortisol and corticosterone. Dexamethasone poorly penetrates the blood–brain barrier into the central nervous system due to binding to P-glycoprotein. However, higher doses of dexamethasone override the export capacity of P-glycoprotein and enter the brain to produce central activation of GRs. In conjunction with the suppression of endogenous corticosteroids by dexamethasone, this results in skewed ratios of activation of peripheral versus central GRs as well as skewed ratios of activation of GRs versus MRs when compared to non-synthetic corticosteroids. These differences can have significant clinical relevance.
O'Mahoney (1907), United States senator from Wyoming James W. Mott (1909), U.S. congressman from Oregon Emanuel Celler (1910), 39th dean of the United States House of Representatives; U.S. congressman from New York William Langer (1910), United States senator and governor of North Dakota Laurence Steinhardt (1913), former U.S. ambassador to Sweden, Peru, the Soviet Union, Turkey, Czechoslovakia and Canada; the first U.S. ambassador to be killed in office Henry Frank Holthusen (1915), lawyer, diplomat, U.S. ambassador to Czechoslovakia nominee Samuel Irving Rosenman (1915), 1st White House counsel to presidents Franklin D. Roosevelt and Harry S. Truman, name partner of Katten Muchin Rosenman Frederic René Coudert Jr. (1918), U.S. congressman from New York Harold F. Linder (1921), president of the Export-Import Bank of the United States 1961–1968; former U.S ambassador to Canada Arthur Levitt Sr. (1921), longest-serving New York state comptroller; father of Arthur Levitt, chairman of the United States Securities and Exchange Commission Joseph Zaretzki (1922), majority leader of the New York State Senate 1966–1974 Louis M. Rousselot (1923), assistant secretary of defense for health and environment 1970–1971 Joseph Campbell (1924), fourth comptroller general of the United States Arthur F. Burns (1925), chairman of the Federal Reserve and U.S. ambassador to West Germany Bernard M. Shanley (1925), White House counsel 1953–1955; secretary to the president of the United States under Dwight D. Eisenhower 1955–1957 Joseph F.
That same year, Sonic Healthcare acquired 56% ownership of the Schottdorf Group in Germany, 72% ownership of the Independent Practitioner Network Limited (IPN), the pathology operations of Endeavour HealthCare in NSW and WA merging them into Douglass Hanly Moir Pathology and Clinipath Pathology, and (through IPN) Endeavour's medical centre operations. In 2005, Sonic Healthcare acquired an 82% interest in Clinical Pathology Laboratories, Inc., the largest privately owned regional pathology laboratory in the United States.
== History == Dextromoramide was discovered and patented in 1956 by Paul Janssen at Janssen Pharmaceuticals, who also discovered fentanyl, another important synthetic opioid, widely used to treat pain and in combination with other drugs as an anaesthetic, as well as haloperidol, piritramide, the loperamide-diphenoxylate series and other important drugs. Dextromoramide was much favoured by drug users in Australia in the 1970s and the United Kingdom. It has the main proprietary name of Palfium amongst others, though as of mid-2004 the drug was discontinued in the UK due to limited supplies of precursor chemicals. Although this is true, it is believed there was an approximate one year shortage of Dextromoramide and the real reason that Palfium was not put back into production for the UK market is because of how addictive and potent it is as an oral painkiller. Dependence liability is similar to morphine, but with a less severe withdrawal syndrome. The only European countries that now use the brand Palfium are the Netherlands, Ireland and Luxembourg. It is presumably able to be imported into other Schengen zone countries under Title 76 of said treaty coming into force in 2002. It is a Schedule I Narcotic controlled substance in the United States, with a DEA ACSCN of 9613 and an annual aggregate manufacturing quota of zero as of 2013, and had been out of use in the United States for around a decade when the new Controlled Substances Act 1970 was promulgated. The salts of dextromoramide in use are the hydrochloride (free base conversion ratio 0.915) and tartrate (0.724).
The CEPI, the WHO, and charitable vaccine organizations, such as the Gates Foundation and GAVI, raised over US$20 billion during the first half of 2020, to fund vaccine development and preparedness for vaccinations, particularly for children in under-developed countries. CEPI, which was created to monitor fair distribution of infectious disease vaccines to low- and middle-income countries, has recommended considering manufacturing capacity, financing and purchasing, and releasing vaccine developers from liability. Despite opposition from some vaccine manufacturers, CEPI revised its February 2020 equitable access policy to apply specifically to its COVID‑19 vaccine funding:
Sources: en.wikipedia.org
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.
Mass spectrometry, such as LC-MS or MALDI-TOF, confirms the molecular mass and can reveal sequence-related impurities. Reversed-phase HPLC is used for purity, and peptide mapping or amino acid analysis can support sequence identity. No single method establishes every quality attribute.
No. AOD9604 is a short synthetic fragment of the hGH sequence, not the full 191-amino-acid hormone. It lacks the regions that mediate hGH receptor activation and growth-promoting effects. Products labeled as AOD9604 should not be assumed to have the same properties as hGH.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.